Last quarter (Q2 2025), Galectin Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Galectin Therapeutics's net income was $-7.52M. See Galectin Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -37.00K	$ -33.00K	$ -32.00K	$ -41.00K	$ -36.00K
Operating Expenses	$ 42.43M	$ 38.04M	$ 38.35M	$ 30.18M	$ 23.44M
Depreciation and Amortization	$ 37.00K	$ 33.00K	$ 32.00K	$ 41.00K	$ 36.00K
EBITDA	$ -41.47M	$ -38.24M	$ -37.71M	$ -30.00M	$ -23.34M
Operating Income	$ -42.43M	$ -38.07M	$ -38.35M	$ -30.18M	$ -23.44M
Other Income/Expenses	$ -4.61M	$ -2.99M	$ -424.00K	$ -348.00K	$ -21.00K
Pretax Income	$ -47.05M	$ -41.07M	$ -38.78M	$ -30.53M	$ -23.46M
Net Income	$ -47.05M	$ -41.07M	$ -38.78M	$ -30.53M	$ -23.46M
Per Share Metrics
Basic EPS	$ -0.76	$ -0.74	$ -0.65	$ -0.52	$ -0.41
Diluted EPS	$ -0.76	$ -0.74	$ -0.65	$ -0.52	$ -0.41
Weighted Average Shares Outstanding	62.31M	60.16M	59.39M	58.53M	57.03M
Weighted Average Shares Outstanding (Diluted)	62.31M	60.16M	59.39M	58.53M	57.03M

Currency in USD

Galectin Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing